Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Lifesci Capital Issues Positive Forecast for Kodiak Sciences (NASDAQ:KOD) Stock Price

Summary
Lifesci Capital upped their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the stock an "outperform" rating in a research report on Monday.

6 Articles

GloboGlobo
Lean Right

Discovered Medicines for Retinal Disease Makes Kodiak Sciences Shoot

Kodiak Sciences' actions more than doubled on Monday (28) after two experimental drugs for eye diseases were successful in an advanced phase study, positioning the biopharmaceutical company to take its first product to the market. Exclusive material for subscribers. To have full access, access the link of the material and register.

·Rio de Janeiro, Brazil
Read Full Article
MarketBeatMarketBeat
Center

Kodiak Sciences (NASDAQ:KOD) Hits New 52-Week High - Still a Buy?

Kodiak Sciences (NASDAQ:KOD) Hits New 52-Week High - What's Next?

·Sioux Falls, United States
Read Full Article
Investor's Business DailyInvestor's Business Daily
Lean Right

Why This Regeneron Eye Rival Just Catapulted More Than 170%

Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.

·Los Angeles, United States
Read Full Article
biopharmadive.combiopharmadive.com
Center

Kodiak skyrockets on positive study data for 2 eye drugs

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

Read Full Article
BizTocBizToc

Kodiak Stock Gains 183% as New Eye Drugs Take Aim at Regeneron’s Eylea

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Read Full Article
endpoints.newsendpoints.news

Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor

Kodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet age-related macular ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news on Monday, September 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Stock Markets icon

Stock Markets

Palo Alto icon

Palo Alto

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal